CA2557615A1 - Treatment of haemorrhagic shock using complement 5a receptor inhibitors - Google Patents

Treatment of haemorrhagic shock using complement 5a receptor inhibitors Download PDF

Info

Publication number
CA2557615A1
CA2557615A1 CA002557615A CA2557615A CA2557615A1 CA 2557615 A1 CA2557615 A1 CA 2557615A1 CA 002557615 A CA002557615 A CA 002557615A CA 2557615 A CA2557615 A CA 2557615A CA 2557615 A1 CA2557615 A1 CA 2557615A1
Authority
CA
Canada
Prior art keywords
side chain
shock
inhibitor
group
haemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002557615A
Other languages
English (en)
French (fr)
Inventor
Denis W. Harkin
Thomas F. Lindsay
Steven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of CA2557615A1 publication Critical patent/CA2557615A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002557615A 2003-05-15 2004-05-14 Treatment of haemorrhagic shock using complement 5a receptor inhibitors Abandoned CA2557615A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003902354 2003-05-15
AU2003902354A AU2003902354A0 (en) 2003-05-15 2003-05-15 Treatment of haemorrhagic shock
PCT/AU2004/000642 WO2004100975A1 (en) 2003-05-15 2004-05-14 TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS

Publications (1)

Publication Number Publication Date
CA2557615A1 true CA2557615A1 (en) 2004-11-25

Family

ID=31501223

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002557615A Abandoned CA2557615A1 (en) 2003-05-15 2004-05-14 Treatment of haemorrhagic shock using complement 5a receptor inhibitors

Country Status (5)

Country Link
EP (1) EP1635857A1 (ja)
JP (1) JP2006528208A (ja)
AU (1) AU2003902354A0 (ja)
CA (1) CA2557615A1 (ja)
WO (1) WO2004100975A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3078658B1 (en) 2008-12-22 2019-04-10 ChemoCentryx, Inc. C5ar antagonists
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
WO2016053890A1 (en) 2014-09-29 2016-04-07 Chemocentryx, Inc. PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
RU2742888C2 (ru) 2016-01-14 2021-02-11 Кемосентрикс, Инк. Способ лечения с3-гломерулопатии
MA44629A (fr) 2016-04-04 2021-03-24 Chemocentryx Inc Antagonistes de c5ar solubles
US10683294B2 (en) 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
JP7141130B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
AU2018359214A1 (en) 2017-10-30 2020-04-16 Chemocentryx, Inc. Deuterated compounds as immunomodulators
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202005799XA (en) 2017-12-22 2020-07-29 Chemocentryx Inc DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
CA3095184A1 (en) 2018-04-02 2019-10-10 Chemocentryx, Inc. Prodrugs of fused-bicyclic c5ar antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist

Also Published As

Publication number Publication date
WO2004100975A1 (en) 2004-11-25
AU2003902354A0 (en) 2003-05-29
JP2006528208A (ja) 2006-12-14
EP1635857A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
KR19990063958A (ko) 지혈성 디펩티드의 약학 조성물 및 이의 사용방법
US11154587B2 (en) Use of peptides to stimulate the immune system
AU2021202310A1 (en) Compositions and methods for treating acute radiation syndrome
US20220160820A1 (en) Modulators of complement activity
US20100267639A1 (en) Treatment of osteoarthritis
CA2557615A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
US5498601A (en) Platelet aggregation-inhibiting peptides
RU2313364C2 (ru) Способы индукции длительного иммунного ответа
RU2545718C2 (ru) Лечение сосудистых осложнений диабета
US6864237B2 (en) Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
WO2009151714A2 (en) Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
WO2015022326A1 (en) Peptides as active agents for treating primary graft dysfunction
KR100186656B1 (ko) 신규한 펩타이드, 및 전기 펩타이드를 이용하는 혈소판 응집저해제, 체외순환하는 혈액의 혈액응고 저해제, 세포점착저해제, 종양전이 저해제, 수혈용 혈소판 제제의 보호제, 수혈용 혈소판 제제 및 혈소판 제제 팩
US20060276390A1 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
AU2004238089A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
WO2004004551A2 (en) Alpha-melanocyte stimulating hormone peptides protection in organ transplantation
KR100266929B1 (ko) 약학적 라이신-함유 폴리펩티드 조성물 및 그의 사용방법
US20100189802A1 (en) Method for treatment of vascular hyperpermeability
AU2018210166A1 (en) Compositions and methods for treating iron overload
US20070054841A1 (en) Method of treatment of systemic injury secondary to burns
US20100099602A1 (en) Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury
ES2366538T3 (es) Tratamiento de la enfermedad inflamatoria intestinal.
WO2022177635A2 (en) Compositions and methods for microbial disease treatment
WO2011093851A1 (en) Method for treatment of vascular hyperpermeability
KR0133998B1 (ko) 위장질환 치료용 의약 조성물

Legal Events

Date Code Title Description
FZDE Discontinued